// App-Quantinova.ai

168 : Body mass index does not influence the efficacy of abatacept in patients with psoriatic arthritis: results from the ASTRAEA trial

Researchers

Presenter

  • Iain McInnes

Principal Investigators

  • Gianfranco Ferraccioli

  • Maria-Antonietta DAgostino

  • Manuela Le Bars

  • Subhashis Banerjee

  • Harris A Ahmad

  • Yedid Elbez

  • June Ye

  • Philip Mease

Medical Centers

  • Glasgow Biomedical Research Centre, University of Glasgow, Glasgow

  • Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy

  • Department of Rheumatology, Hôpital Ambroise Paré, Boulogne-Billancourt, FRANCE

  • Medical Affairs, Bristol-Myers Squibb, Rueil-Malmaison, FRANCE

  • Immunoscience Global Clinical Research, Bristol-Myers Squibb, Princeton, NJ, USA

  • Global Development and Medical Affairs, Bristol-Myers Squibb, Princeton, NJ, USA

  • Biostatistics, Excelya, Boulogne-Billancourt, FRANCE

  • Biostatistics, Bristol Myers Squibb, Princeton, NJ

  • Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, WA

Locations

  • United Kingdom

  • Italy

  • France

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Psoriatic arthritis

  • Obesity

  • Inflammatory Arthritis

Biomarkers

  • C reactive protein

  • Complement Factor B

  • Malondialdehyde

  • Body mass index

Drug/Treatment

  • Abatacept

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Open Label

Phase

  • III

Study Id's

  • NCT01860976

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved